MaxWell Biosystems exhibited MaxOne and its applications for Cardiac Safety Pharmacology at the 2016 Safety Pharmacology Society (SPS) / Japanese Safety Pharmacology Society (JSPS) / Canadian Society of Pharmacology and Therapeutics (CSPT) Joint Meeting in Vancouver, BC, Canada. The meeting, held from the 18th to 21st of September 2016, had over 568 attendees from around the world, with 253 abstracts presented and 51 exhibiting companies.
MaxWell Biosystems received the ETH spin-off label and joins the strong list of ETH spin-off companies. MaxWell Biosystems continues to be in close collaboration with Prof. Dr. Andreas Hierlemann and the Bio Engineering Laboratory, Department of Biosystems Science and Engineering in Basel.
We are delighted to announce the official registration of MaxWell Biosystems AG in Canton Basel-City, Switzerland. MaxWell Biosystems is now part of Basel’s booming life science and tech start-up community with its close vicinity to multinational biotech and pharmaceutical companies.
MaxWell Biosystems gets through the first round of Venture Kick and receives CHF 10,000 grant. The team will attend the kickers camp on September and then proceed to Stage 2 of the competition, with an opportunity to win an additional CHF 20,000. See the VentureKick news here.